It did not last because the job was not intended to, since Merlin was only helping with the electrical engineering aspect of the device. I have to correct my previous post. The catheter device itself is being worked by Rev.1, who is developing a tissue sensing and feedback control of electroporation pulse trains in order to attain optimal gene transfer and minimal electroporation-mediated tissue damage. Most likely, the electrical part of the job by Merlin was completed and Oncosec is getting closer to attaining a device to treat visceral tumors.
Dr. Pierce explained, “Taken together, these engineering advances can enable access and high-efficiency gene delivery to tumors throughout the body. This is key as we move forward in developing OncoSec’s pipeline of novel intratumoral therapies”.
“Our partnership with Rev.1 Engineering and internal bioengineering expertise have allowed OncoSec to enhance our ImmunoPulse platform and position the Company as a leader in gene electro-transfer technologies in cancer immunotherapy,” says Punit.
“We are also strengthening our intellectual property portfolio in the area of gene and drug delivery via electroporation to reach visceral tumors and enhance the uptake of therapeutic agents.”
Coincidently to that last statement, Oncosec last week attained an additional trademark for ImmunoPulse representing the good and services of DNA compounds for medical research, as well as pharmaceutical preparations that are comprised of DNA compounds for the treatment of tumors. Adding to the other ImmunoPulse trademark the company had for medical devices or therapy to treat disease by using electroporation to deliver agents to stimulate a systemic immune response.
